193 related articles for article (PubMed ID: 10616203)
1. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control.
Gerharz CD; Ramp U; Déjosez M; Mahotka C; Czarnotta B; Bretschneider U; Lorenz I; Müller M; Krammer PH; Gabbert HE
Lab Invest; 1999 Dec; 79(12):1521-34. PubMed ID: 10616203
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
Wu XX; Mizutani Y; Kakehi Y; Yoshida O; Ogawa O
Cancer Res; 2000 Jun; 60(11):2912-8. PubMed ID: 10850437
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Déjosez M; Ramp U; Mahotka C; Krieg A; Walczak H; Gabbert HE; Gerharz CD
Cell Death Differ; 2000 Nov; 7(11):1127-36. PubMed ID: 11139287
[TBL] [Abstract][Full Text] [Related]
4. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
5. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
7. Fas/APO-1-mediated apoptosis of human renal cell carcinoma.
Nonomura N; Miki T; Yokoyama M; Imazu T; Takada T; Takeuchi S; Kanno N; Nishimura K; Kojima Y; Okuyama A
Biochem Biophys Res Commun; 1996 Dec; 229(3):945-51. PubMed ID: 8954998
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis.
Mizutani Y; Nakanishi H; Li YN; Matsubara H; Yamamoto K; Sato N; Shiraishi T; Nakamura T; Mikami K; Okihara K; Takaha N; Ukimura O; Kawauchi A; Nonomura N; Bonavida B; Miki T
Int J Oncol; 2007 Apr; 30(4):919-25. PubMed ID: 17332931
[TBL] [Abstract][Full Text] [Related]
9. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.
Griffith TS; Fialkov JM; Scott DL; Azuhata T; Williams RD; Wall NR; Altieri DC; Sandler AD
Cancer Res; 2002 Jun; 62(11):3093-9. PubMed ID: 12036919
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of CD95 receptor expression in clear cell renal carcinomas.
Ramp U; Bretschneider U; Ebert T; Karagiannidis C; Willers R; Gabbert HE; Gerharz CD
Hum Pathol; 2003 Feb; 34(2):174-9. PubMed ID: 12612886
[TBL] [Abstract][Full Text] [Related]
11. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.
Perabo FG; Kamp S; Schmidt D; Lindner H; Steiner G; Mattes RH; Wirger A; Pegelow K; Albers P; Kohn EC; von Ruecker A; Mueller SC
Br J Cancer; 2001 May; 84(10):1330-8. PubMed ID: 11355943
[TBL] [Abstract][Full Text] [Related]
12. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines.
Weller M; Frei K; Groscurth P; Krammer PH; Yonekawa Y; Fontana A
J Clin Invest; 1994 Sep; 94(3):954-64. PubMed ID: 7521890
[TBL] [Abstract][Full Text] [Related]
13. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
14. Fas/APO-1 gene transfer for human malignant glioma.
Weller M; Malipiero U; Rensing-Ehl A; Barr PJ; Fontana A
Cancer Res; 1995 Jul; 55(13):2936-44. PubMed ID: 7540953
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma.
Ramp U; Jaquet K; Reinecke P; Nitsch T; Gabbert HE; Gerharz CD
Lab Invest; 1997 May; 76(5):739-49. PubMed ID: 9166292
[TBL] [Abstract][Full Text] [Related]
16. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis.
von Reyher U; Sträter J; Kittstein W; Gschwendt M; Krammer PH; Möller P
Cancer Res; 1998 Feb; 58(3):526-34. PubMed ID: 9458101
[TBL] [Abstract][Full Text] [Related]
17. Deficient activation of CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma.
Ramp U; Dejosez M; Mahotka C; Czarnotta B; Kalinski T; Wenzel M; Lorenz I; Müller M; Krammer P; Gabbert HE; Gerharz CD
Br J Cancer; 2000 Jun; 82(11):1851-9. PubMed ID: 10839301
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
Huerta-Yepez S; Vega M; Garban H; Bonavida B
Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CD95 apoptotic signaling by interferon-gamma in human osteoarthritic chondrocytes is associated with increased expression of FLICE inhibitory protein.
Grassi F; Piacentini A; Cristino S; Toneguzzi S; Facchini A; Lisignoli G
Arthritis Rheum; 2004 Feb; 50(2):498-506. PubMed ID: 14872492
[TBL] [Abstract][Full Text] [Related]
20. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
Fulda S; Meyer E; Debatin KM
Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
